BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells

Blood

Volumn 122, Issue 16, 2013, Pages 2864-2876

  Beurlet, Stephanie ^a,b   Omidvar, Nader ^c   Gorombei, Petra ^a,b   Krief, Patricia ^a,b   Le Pogam, Carole ^a,b   Setterblad, Niclas ^b   De La Grange, Pierre ^b   Leboeuf, Christophe ^a,b,d   Janin, Anne ^a,b,d   Noguera, Maria Elena ^d   Hervatin, Florence ^e   Sarda Mantel, Laure ^b,f   Konopleva, Marina ^g   Andreeff, Michael ^g   Tu, Andrea W ^h   Fan, Alice C ⁱ   Felsher, Dean W ⁱ   Whetton, Anthony ^j   Pla, Marika ^a,b   West, Robert ^c   Fenaux, Pierre ^a,b,d   Chomienne, Christine ^a,b,d   Padua, Rose Ann ^a,b,d   more..

^a INSERM   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^d SAINT LOUIS HOSPITAL   (France)

^e SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^f CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^g UNIVERSITY OF TEXAS   (United States)

^h ProteinSimple   (United States)

ⁱ STANFORD CANCER INSTITUTE   (United States)

^j UNIVERSITY OF MANCHESTER   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 7 AMINODACTINOMYCIN; CASPASE 3; LIN PROTEIN; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BCL 2; PROTEIN KINASE B; STEM CELL ANTIGEN 1; STEM CELL FACTOR; TECHNETIUM 99M; TUMOR PROTEIN; UNCLASSIFIED DRUG; ABT-737; BIPHENYL DERIVATIVE; LY ANTIGEN; LY6A PROTEIN, MOUSE; MEMBRANE PROTEIN; NITROPHENOL; PIPERAZINE DERIVATIVE; RAS PROTEIN; STEM CELL FACTOR RECEPTOR; SULFONAMIDE;

ACUTE MYELOID LEUKEMIA; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLAST CELL; BONE MARROW; CANCER SURVIVAL; CELL MEMBRANE; CELL SURVIVAL; CONTROLLED STUDY; EX VIVO STUDY; EXON; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GRAFT RECIPIENT; IN VIVO STUDY; LEUKEMIA CELL; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; ONCOGENE N RAS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN LOCALIZATION; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SPLEEN CELL; STEM CELL; TUNEL ASSAY; ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINEAGE; CELL PROLIFERATION; CELL TRANSFORMATION; CELL TRANSPLANTATION; CYTOLOGY; DISEASE MODEL; GENE EXPRESSION REGULATION; METABOLISM; MITOCHONDRION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, LY; BIPHENYL COMPOUNDS; CELL LINEAGE; CELL MEMBRANE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELL TRANSPLANTATION; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, LEUKEMIC; LEUKEMIA, MYELOID, ACUTE; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; MITOCHONDRIA; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-KIT; RAS PROTEINS; STEM CELLS; SULFONAMIDES;

EID: 84891520098     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-07-445635     Document Type: Article

References (49)

1. Padua RA, Guinn BA, Al-Sabah AI, et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia. 1998;12(6):887-892.
2. Kogan SC, Lagasse E, Atwater S, et al. The PEBP2betaMYH11 fusion created by Inv(16) (p13;q22) in myeloid leukemia impairs neutrophil maturation and contributes to granulocytic dysplasia. Proc Natl Acad Sci USA. 1998;95(20): 11863-11868.
3. Omidvar N, Kogan S, Beurlet S, et al. BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. Cancer Res. 2007;67(24):11657-11667.
4. Lagasse E, Weissman IL. bcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages. J Exp Med. 1994;179(3): 1047-1052.
5. Parker JE, Mufti GJ. The myelodysplastic syndromes: a matter of life or death. Acta Haematol. 2004;111(1-2):78-99.
6. Parker JE, Mufti GJ, Rasool F, et al. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood. 2000;96(12):3932-3938.
7. Parker JE, Fishlock KL, Mijovic A, et al. 'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins. Br J Haematol. 1998;103(4):1075-1082.
8. Karakas T, Miething CC, Maurer U, et al. The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia. Leukemia. 2002;16(5): 846-854.
9. Karakas T, Maurer U, Weidmann E, et al. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol. 1998;9(2):159-165.
10. Le Pogam C, Krief P, Beurlet S, et al. Localization of the NRAS:BCL-2 complex determines antiapoptotic features associated with progressive disease in myelodysplastic syndromes. Leuk Res. 2012;37(3):312-319.
11. Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10(5): 375-388.
12. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006;10(5): 389-399.
13. Mason KD, Vandenberg CJ, Scott CL, et al. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc Natl Acad Sci USA. 2008;105(46):17961-17966.
14. Hann CL, Daniel VC, Sugar EA, et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res. 2008;68(7):2321-2328.
15. High LM, Szymanska B, Wilczynska-Kalak U, et al. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol. 2010;77:483-494.
16. Olberding KE, Wang X, Zhu Y, et al. Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression. Cancer Biol Ther. 2010;10(9): 918-929.
17. Zhang C, Cai TY, Zhu H, et al. Synergistic Antitumor Activity of Gemcitabine and ABT-737 In Vitro and In Vivo through Disrupting the Interaction of USP9X and Mcl-1. Mol Cancer Ther. 2011;10(7):1264-1275.
18. Miller LA, Goldstein NB, Johannes WU, et al. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. J Invest Dermatol. 2009;129(4):964-971.
19. Zhang W, Konopleva M, Ruvolo VR, et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia. 2008;22(4):808-818.
20. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421-3428.
21. Gandhi L, Camidge DR, Ribeiro de Oliveira M, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011;29(7):909-916.
22. Hallek M, Pflug N. State of the art treatment of chronic lymphocytic leukaemia. Blood Rev. 2011; 25(1):1-9.
23. Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2011;30(5): 488-496.
24. Kogan SC, Ward JM, Anver MR, et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood. 2002; 100(1):238-245.
25. Cabreiro F, Picot CR, Perichon M, et al. Overexpression of mitochondrial methionine sulfoxide reductase B2 protects leukemia cells from oxidative stress-induced cell death and protein damage. J Biol Chem. 2008;283(24): 16673-16681.
26. Novo D, Perlmutter NG, Hunt RH, et al. Accurate flow cytometric membrane potential measurement in bacteria using diethyloxacarbocyanine and a ratiometric technique. Cytometry. 1999;35(1): 55-63.
27. Fan AC, Deb-Basu D, Orban MW, et al. Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. Nat Med. 2009;15(5):566-571.
28. de la Grange P, Dutertre M, Martin N, et al. FAST DB: a website resource for the study of the expression regulation of human gene products. Nucleic Acids Res. 2005;33(13):4276-4284.
29. de la Grange P, Gratadou L, Delord M, et al. Splicing factor and exon profiling across human tissues. Nucleic Acids Res. 2010;38(9): 2825-2838.
30. Zhang H, Nimmer PM, Tahir SK, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 2007;14(5):943-951.
31. Cencic R, Carrier M, Trnkus A, et al. Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells. Leuk Res. 2010; 34(4):535-541.
32. Coleman ML, Marshall CJ, Olson MF. Ras promotes p21(Waf1/Cip1) protein stability via a cyclin D1-imposed block in proteasomemediated degradation. EMBO J. 2003;22(9): 2036-2046.
33. Ezzoukhry Z, Louandre C, Francois C, et al. The Bcl-2 homology domain 3 (BH3) mimetic ABT-737 reveals the dynamic regulation of bad, a proapoptotic protein of the Bcl-2 family, by Bcl-xL. Mol Pharmacol. 2011;79(6):997-1004.
34. Gatza CE, Oh SY, Blobe GC. Roles for the type III TGF-beta receptor in human cancer. Cell Signal. 2010;22(8):1163-1174.
35. Schoenwaelder SM, Jarman KE, Gardiner E, et al. Bcl-xL inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood. 2011; 118(6):1663-1674.
36. Nilsson SK, Johnston HM, Whitty GA, et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood. 2005;106(4):1232-1239.
37. Flamant S, Kortulewski T, Dugray A, et al. Osteopontin is upregulated by BCR-ABL. Biochem Biophys Res Commun. 2005;333(4): 1378-1384.
38. Hickey FB, England K, Cotter TG. Bcr-Abl regulates osteopontin transcription via Ras, PI-3K, aPKC, Raf-1, and MEK. J Leukoc Biol. 2005;78(1):289-300.
39. Vogler M, Butterworth M, Majid A, et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood. 2009;113(18):4403-4413.
40. Rassool FV, Gaymes TJ, Omidvar N, et al. Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? Cancer Res. 2007;67(18):8762-8771.
41. Denis GV, Yu Q, Ma P, et al. Bcl-2, via its BH4 domain, blocks apoptotic signaling mediated by mitochondrial Ras. J Biol Chem. 2003;278(8): 5775-5785.
42. Glaser SP, Lee EF, Trounson E, et al. Antiapoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 2012;26(2):120-125.
43. Chen S, Dai Y, Harada H, et al. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res. 2007;67(2):782-791.
44. Townsend KJ, Zhou P, Qian L, et al. Regulation of MCL1 through a serum response factor/Elk-1-mediated mechanism links expression of a viability-promoting member of the BCL2 family to the induction of hematopoietic cell differentiation. J Biol Chem. 1999;274(3): 1801-1813.
45. Domina AM, Vrana JA, Gregory MA, et al. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene. 2004;23(31): 5301-5315.
46. Konopleva M, Milella M, Ruvolo P, et al. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia. 2012;26(4):778-787.
47. Suela J, Alvarez S, Cigudosa JC. DNA profiling by arrayCGH in acute myeloid leukemia and myelodysplastic syndromes. Cytogenet Genome Res. 2007;118(2-4):304-309.
48. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202-208.
49. Davids MS, Letai A. ABT-199: taking dead aim at BCL-2. Cancer Cell. 2013;23(2):139-141.